Quick Answer
NextCure, Inc. reported Operating Income Loss of -$57.62 million for the year ending 2025.
- NextCure, Inc. showed an increase of +3.6% in Operating Income Loss from 2024 to 2025.
- This data is from NextCure, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$5.01 million | Q2 2018: -$5.30 million | Q3 2018: -$5.82 million | Q1 2019: -$6.82 million | Q2 2019: -$8.96 million | Q3 2019: -$9.70 million | Q1 2020: $8.21 million | Q2 2020: -$15.80 million | Q3 2020: -$17.40 million | Q1 2021: -$17.23 million | Q2 2021: -$17.95 million | Q3 2021: -$18.51 million | Q1 2022: -$20.77 million | Q2 2022: -$18.13 million | Q3 2022: -$19.24 million | Q1 2023: -$17.07 million | Q2 2023: -$19.16 million | Q3 2023: -$15.62 million | Q1 2024: -$18.30 million | Q2 2024: -$16.49 million | Q3 2024: -$12.50 million | Q1 2025: -$11.62 million | Q2 2025: -$27.29 million | Q3 2025: -$8.95 million.
- Over the full 8 years of available data (2018 to 2025), NextCure, Inc.'s Operating Income Loss has declined by 148.4%.
- Historical annual values: Fiscal year 2025: -$57.62 million | Fiscal year 2024: -$59.75 million | Fiscal year 2023: -$67.64 million | Fiscal year 2022: -$75.91 million | Fiscal year 2021: -$70.77 million | Fiscal year 2020: -$41.23 million | Fiscal year 2019: -$37.48 million | Fiscal year 2018: -$23.20 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: